ABSTRACT
It has been found that long noncoding RNA (lncRNA) are abnormally expressed in lymphoma and play an important role in its pathogenesis. Through the detection and analysis of lncRNA, it was found that lncRNA could be used as an excellent biomarker for the diagnosis and prognosis of cancer. In lymphoma, abnormal lncRNA expression is associated with the patient's clinical characteristics, it can be used to determine the prognosis of the patient and serve as a therapeutic target in the disease.
Subject(s)
Biomarkers, Tumor , Gene Expression Regulation, Neoplastic , Lymphoma/genetics , RNA, Long Noncoding/genetics , Animals , Gene Expression Profiling , Humans , Lymphoma/diagnosis , Lymphoma/mortality , Lymphoma/therapy , Molecular Targeted Therapy , Prognosis , RNA InterferenceABSTRACT
<p><b>OBJECTIVE</b>To investigate the expression of miR-224 in diffuse large B cell lymphoma (DLBCL) and its relationship with clinical pathological features and prognosis.</p><p><b>METHODS</b>Real-time PCR was used to detect the expression of miR-224 in 168 DLBCL and 25 normal lymphoid tissues.</p><p><b>RESULTS</b>The expression of miR-224 in DLBCL (0.97 ± 0.33) was significantly lower than that in normal lymphoid tissues (1.87 ± 0.43, P<0.05). There were no significant correlations between the miR-224 expression and age (P=0.434), gender (P=0.613) tumors stage (P=0.250), IPI (P=0.355) and lactate dehydrogenase (P=0.398). Using the median of miRNA-224 expression as threshold, we subdivided patients into low and high expression group. The five-year progression-free survival and overall survival were significantly lower in low expression group as compared to those in high expression group.</p><p><b>CONCLUSION</b>miR-224 expression may play an important role in the development and progression of DLBCL and could be prognostic significance.</p>
